The post-marketing international Global Adherence Project investigated adherence to disease-modifying therapy for relapsing-remitting multiple sclerosis. We report adherence data from the first 2 years in the Spanish subset of patients (n = 254 at baseline). The overall adherence rate was 85.4%. Patients taking intramuscular (IM) interferon-β (IFNβ)-1a were significantly more adherent (96.4%) compared with patients taking subcutaneous (SC) IFNβ-1a 22 µg (79.1%; p = 0.0064), SC IFNβ-1a 44 µg (79.6%; p = 0.0064) and glatiramer acetate (82.7%; p = 0.0184). At year 1 (n = 142), the overall adherence rate was 86.6%. Patients on IM IFNβ-1a were significantly more adherent than patients on SC IFNβ-1a 22 µg (93.9 vs. 66.7%; p = 0.0251). At year 2 (n = 131), the overall adherence rate was 82% (87.5% for IM IFNβ-1a, 80.0% for SC IFNβ-1a 22 µg, 77.8% for SC IFNβ-1a 44 µg, 85.2% for IFNβ-1b, and 80.0% for glatiramer acetate). In conclusion, adherence remained high among all disease-modifying therapies over the first 2 years of the study and was significantly higher for IM IFNβ-1a, at visit 1, compared with SC IFNβ-1a.

World Health Organization Report: Adherence to Long-Term Therapies. Geneva, WHO, 2003.
Tremlett HL, Ogel J: Interrupted therapy: stopping and switching of the β-interferons prescribed for MS. Neurology 2003;61:551–554.
Río J, Porcel J, Téllez N, Sánchez-Betancourt A, Tintoré M, Arévalo MJ, Nos C, Montalban X: Factors related with treatment adherence to interferon-β and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11:306–309.
Taus C, Taffi R, Morelli M, Fie A, Angeleri VA, Sgolastra M: Adherence to IFN-β therapy in MS: an Italian clinical setting. Mult Scler 2001;7(suppl 1):S65.
Devonshire V, Lapierre Y, Macdonell R, et al: The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2010 (in press).
Frohman E, Phillips T, Kokel K, Van Pelt J, O’Leary S, Gross S, Hawker K, Racke M: Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002;8:227–236.
Treadaway KD, Brannon KD, Morrison A, Remmington GM: Factors that influence adherence with disease-modifying therapy in multiple sclerosis (abstract). Neurology 2006;66(suppl 2):A30.
Holland N, Wiesel P, Cavallo P, Edwards C, Halper J, Kalb R, Morgante L, Namey M, O’Leary M, Smith-Williamson L: Adherence to disease-modifying therapy in multiple sclerosis: part I. Rehabil Nurs 2001;26:172–176.
Holland N, Wiesel P, Cavallo P, Edwards C, Halper J, Kalb R, Morgante L, Namey M, O’Leary M, Smith-Williamson L: Adherence to disease-modifying therapy in multiple sclerosis: part II. Rehabil Nurs 2001;26:221–226.
Fiore AP, Fragoso YD: Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months. Arq Neuropsiquiatr 2005;63:738–740.
Duque B, Sepulcre J, Bejarano B, et al: Memory decline evolves independently of disease activity in MS. Mult Scler 2008;14:947–953.
Bruce JM, Hancock LM, Arnett P, Lynch S: Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med 2010;33:219–227.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.